Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.
As of April 26, 2021, three MTGs related to eHealth technology are in development with the scheduled publication date:
- myCOPD for self-management of chronic obstructive pulmonary disease (COPD) – assessment within the pilot project for digital health technologies (DHT pilot). It is an application for smartphones or tablets used as an integrated online education, self-management, symptom reporting, and pulmonary rehabilitation system;
- Sleepio for adults with difficulty sleeping - a self-help sleep improvement program based on
cognitive behavioral therapy for insomnia (CBT‑I);
- KardiaMobile for the ambulatory detection of atrial fibrillation - a portable single-lead electrocardiogram (ECG) recorder. The monitor works with a compatible mobile device (such as a smartphone or tablet) running the Kardia app, which analyses the ECG recording and sends it to a healthcare professional for interpretation.
The Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.
As of April 26, 2021, one DG concerned eHealth technology are in development with the scheduled publication date:
- Artificial intelligence software for analyzing CT brain scans – to assess the clinical and cost-effectiveness of artificial intelligence (AI) software for automated detection of suspected brain abnormalities in CT scans from people with a suspected acute stroke;
MedTech Innovation Briefing (MIB) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations.
As of April 26, 2021, nine MIBs concerned eHealth technology are in development with the scheduled publication date:
- Personal KinetiGraph – a system that consists of a wrist-worn movement recording device, proprietary algorithms, and a data-driven report (known as the PKG), and provides objective ambulatory continuous assessment of motor complications associated with movement disorders;
- AI Chest Imaging – no further information is available;
- AI Bone Health - no further information is available;
- Syne-COV COVID prediction algorithm – an AI algorithm developed by the UK company Sensyne Health in collaboration with Chelsea & Westminster Hospitals NHS Foundation Trust. It generates a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation, or admission to intensive care;
- MyoVista Wavelet ECG Cardiac Testing Device - a new resting 12-lead electrocardiograph that uses continuous wavelet transform (CWT) signal processing to detect cardiac relaxation abnormalities associated with left ventricular diastolic dysfunction (AI-based technology);
- Acumen IQ sensor for predicting hypotension risk - connects to any existing radial arterial line and uses the proprietary algorithm, developed with machine learning to detect the likelihood of hypotensive trending of a patient mean arterial pressure;
- Oncolaxy for remote follow up of people living with cancer - an advanced e-PRO (electronic Patient Reported Outcomes) system, allowing for home surveillance with qualified alerts by a certified medical algorithm;
- RapidAI for analyzing CT/MRI brain scans – AI-based platform to create high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans, helping hospitals to speed up time-critical triage or transfer decisions and facilitate better patient outcomes;
- Imbio Lung Texture Analysis for measurement of interstitial lung disease (ILD) - applies advanced computer vision to transform a standard chest CT into a detailed map of the lung textures that are key to identifying ILD's and other fibrotic conditions.
See the full details here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).